TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06767839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: The current parameters for the TENS to be applied in the study were determined as 100 Hz, 100 microsecond pulse duration, and asymmetric biphasic waveform. The current intensity will be increased until the person feels a tingling sensation and will be applied for a total of 20 minutes. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Voltage Pulsed Galvanic Stimulation
Description: YVKGS is a monophasic waveform current with double peaks, short pulse duration and a voltage higher than 100 Volts, the frequency of which can be adjusted optionally. In the study, the current parameters of YVKGS were determined as a frequency of 100 Hz, continuous pulse, double peak monophasic waveform. The current intensity will be applied for 20 minutes at the voltage at which the person feels a tingling sensation. Two superficial electrodes will be placed to cover the application area to create an effect in deep tissue.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: The current will be applied to the sham TENS group with the same parameters as the TENS group, and will be reduced and turned off after a while. In TENS application, people normally report that they no longer feel tingling after a few minutes of starting the application. Therefore, it will be explained to the sham TENS group that this situation is normal, and that they no longer feel tingling because they have become accustomed to the applied current.
Study: NCT06769828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-FAPI-46
Description: Ga-68-FAPI-46 PET scan in colorectal cancer
Study: NCT06756581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: baked milk product diet
Description: Elimination of none baked cow milk from diet . Baked cow milk containing diet.
Study: NCT06759558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuranolone
Description: Zuranolone is a neuroactive steroid that works by modulating the activity of the gamma-aminobutyric acid (GABA) receptor in the brain.
Study: NCT06760299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: %25 tension Kinesio tape
Description: I shaped Kinesio tape application with 25% tension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 75% tension Kinesio tape
Description: I shaped Kinesio tape application with 75% tension
Study: NCT06762392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Blood Flow Restriction (BFR) therapy in this study involves the application of a pneumatic cuff around the proximal thigh to restrict arterial blood flow during specific rehabilitation exercises. The cuff will be inflated to achieve 70-80% of arterial occlusion, while participants perform low-intensity resistance exercises at 15-20% of their one-repetition maximum (1RM). BFR therapy will be used during Phase 2 of rehabilitation (weeks 2-12) alongside a standardized rehabilitation protocol. The intervention will be closely monitored by trained Physical Therapists to ensure safety and efficacy, with pressure adjustments made in real-time based on the participant's exercise performance. This intervention distinguishes itself by its use of BFR, a technique that is not part of conventional ACL rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation
Description: The Standard Rehabilitation (RHB) intervention in this study consists of a structured, evidence-based protocol designed to optimize recovery after anterior cruciate ligament (ACL) reconstruction. This rehabilitation protocol is implemented across four phases. The rehabilitation will be supervised by experienced Physical Therapists, and participants will be given a tailored home exercise program to complement the supervised sessions. The intervention aims to optimize recovery, restore function, and reduce the risk of re-injury.
Study: NCT06762600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-4729 injection
Description: HRS-4729 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS-4729 injection placebo
Description: HRS-4729 injection placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531 injection
Description: HRS9531 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 injection placebo
Description: HRS9531 injection placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen
Study: NCT06760559

Intervention type: PROCEDURE
Intervention: Intra-articular corticosteroid injection
Description: Intra-articular hip injections with and without local anastesia and questionnaire about pain and anxiety related to the procedure was administered before and after the injection to the study and control groups.

Intervention type: PROCEDURE
Intervention: Intra-articular corticosteroid injection
Description: Intra-articular hip injections with and without local anastesia and questionnaire about pain and anxiety related to the procedure was administered before and after the injection to the study and control groups.
Study: NCT06768229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of a freeze-dried strains-mix.
Description: One study group of 20 healthy volunteers will consume freeze-dried strains-mix twice per day diluted in 1 glass of still water during 14 consecutive days.
Study: NCT06769191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells injection
Description: Intravenous infusion, single dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allo-HSCT
Description: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Transplantation
Description: Kidney Transplantation
Study: NCT06769048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-matching BI 1584862
Description: Placebo-matching BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862
Study: NCT06766903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All subjects will participate of 8-weeks of exercise training intervention of concurrent training of high-intensity interval training (HIIT) using stationnaire bikes plus resistance training (RT) using free weight under lab conditions.~The exercise program will be monitored by 8-weeks, adapted individually to each participants in terms of exercise intensity an volume.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: All subjects will participate of 8-weeks of exercise training intervention of concurrent training of high-intensity interval training (HIIT) using stationnaire bikes plus resistance training (RT) using free weight under lab conditions.~The exercise program will be monitored by 8-weeks, adapted individually to each participants in terms of exercise intensity an volume.
Study: NCT06772740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization
Description: Middle meningeal artery embolization within 7 days after randomization
Study: NCT06770426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbogen with or without phenyleprhine
Description: Patients will inhale carbogen gas for 10 minutes and rest for 50 minutes. All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: All patients will recevive phenyleprhine to increase blood pressure. Start phenylephrine with 0.5 mg/hr and titrate upto 3.5 mg/hr or systolic blod pressure 200 mmHg.
Study: NCT06775353

Intervention type: DRUG
Intervention: Dexamethasone eyedrop
Description: Infants who developed stages of pretreatment-requiring severe ROP were usually given one eyedrop of dexamethasone daily until the ROP changes regressed.
Study: NCT06776822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilisation
Description: The nervous system establishes programs that control human posture, movement and gait. This 'motor control' is largely established during the first critical years of life. Therefore, the Prague School emphasizes neurodevelopmental aspects of motor control in order to assess and restore dysfunction of the locomotor system and associated syndromes.
Study: NCT06773260

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver and Spleen stiffness measurement.
Description: The use of spleen stiffness measurement to reduce unnecessary upper digestive endoscopies has never been evaluated in this patient setting.
Study: NCT06770023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protek Solo Transseptal Cannula
Description: The Protek Solo Transseptal Cannula ECMO cannula will be placed from the right femoral vein and the drainage cannula will be placed from either the left femoral vein or the right internal jugular vein.
Study: NCT06771453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Educational Tool Regarding Prenatal Genetics
Description: Video education about prenatal genetics will include content regarding aneuploidy screening and diagnostic testing options, how to make a values-based choice, and specifics of risks/benefits/limitations of each type of testing option.
Study: NCT06773585

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI
Description: This study is a minimal-risk study involving non-invasive, non-pharmacological interventions. Participants will continue receiving their usual medication or counseling treatments as part of their routine care during the study.~When participants come to the hospital for assessments, they will engage in clinical assessments and complete questionnaires over a period of 1-2 hours, undergo MRI scans, and participate in virtual environment-based behavioral assessments. They will have the option to take breaks during the assessments and can withdraw from the study at any time without providing a reason.

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychiatric scale assessments, VR-Based Behavioral Assessment, Brain MRI
Description: This study is a minimal-risk study involving non-invasive, non-pharmacological interventions. Participants will continue receiving their usual medication or counseling treatments as part of their routine care during the study.~When participants come to the hospital for assessments, they will engage in clinical assessments and complete questionnaires over a period of 1-2 hours, undergo MRI scans, and participate in virtual environment-based behavioral assessments. They will have the option to take breaks during the assessments and can withdraw from the study at any time without providing a reason.
Study: NCT06778317

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating mSEPT9 Biomarker Testing
Description: This intervention involves the analysis of the circulating epigenetic biomarker mSEPT9 through plasma samples collected from patients with cirrhosis. The mSEPT9 test evaluates the methylation status of the SEPT9 gene promoter using a triplicate assay. A switch in the test status, defined as a transition from triple-negative (no methylation detected in any triplicate) to at least one positive triplicate, is being investigated as a prognostic marker for the development of hepatocellular carcinoma (HCC).~The mSEPT9 test is conducted on plasma samples collected during routine blood draws at each of the 11 scheduled study visits. Samples are processed and analyzed in batches using specialized high-throughput equipment provided by Epigenomics/New Day Diagnostics. Results of the mSEPT9 test are not shared with clinicians during the study period to avoid influencing patient management, ensuring the test is purely investigational in this context.
Study: NCT06779253

Intervention type: DRUG
Group type: OTHER
Intervention: pimicotinib capsules
Description: the effect of multiple oral doses of pimicotinib (50 mg QD) on the pharmacokinetics of fexofenadine (P-gp sensitive substrate), rosuvastatin (BCRP sensitive substrate) and metformin (MATE1 sensitive substrate). Fexofenadine and rosuvastatin will be administered together as a cocktail, and metformin will be given via staggered dosing from the cocktail drugs administration
Study: NCT06779279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water flosser and super flosser
Description: Participant will use in one area superfloss and the other area waterfloss

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic brush
Description: Participant will use orthodontic brush to brush in the upper/lower quadrant
Study: NCT06777966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized tranexamic acid
Description: patients will receive a preoperative nebulizer session of 500 mg of tranexamic acid. To ensure the blinding of the participating anesthetist and patient, patients in this group will receive an intravenous drip of 100 ml of 0.9% normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous tranexamic acid
Description: patients will receive a preoperative intravenous drip of TXA at a dose of 15 mg/kg in 100 ml of normal saline. To ensure blinding this group patients will receive 5 ml of 0.9% normal saline nebulizer session.
Study: NCT06776094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-legged-knee extensor exercise
Description: 1 hour of one-legged-knee-extensor exercise followed by 4 hours of rest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Description: The hyperinsulinemic-euglycemic clamp is a well-established and recognized method for determining glucose uptake at a specific insulin infusion rate. It is a technique with which we have 25 years of uncomplicated experience. During the clamp, insulin (human recombinant insulin) is infused (1.42 mU/kg/min) into an arm vein (antecubital vein), while glucose (20% solution) is administered in an amount adjusted to maintain blood glucose (plasma glucose concentration) at basal levels.~The amount of insulin administered raises the participant's plasma insulin concentration (blood concentration) to approximately 100 μU/mL, which is considered within the physiological range. Blood samples are collected and analyzed continuously for glucose content, allowing for the determination of glucose uptake at the whole-body level and across the legs.~Later, these blood samples will also be analyzed for relevant metabolites and proteins, including insulin, to assess the metabolism of these substances.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Biopsy Medication: Lidocaine
Description: During supine rest, the skin on the outer thigh, approximately 15 cm above the knee, is disinfected with chlorhexidine alcohol. Subsequently, 3-4 mL of local anesthetic (lidocaine 20 mg/mL) is administered into the skin, subcutaneous tissue, and the upper portion of the muscle using a very thin needle. A pinprick test is performed after a few minutes to ensure the anesthetic is effective.~A small incision is then made in the skin and subcutaneous tissue to allow the biopsy needle to pass through to the muscle. Using the biopsy needle, a small sample of muscle tissue (approximately 150 mg) is collected. This may cause some discomfort but is very brief (\~1-2 seconds). The needle is removed, a sterile dressing is applied, and the participant can leave the facility after completing the study.~The biopsy may result in mild muscle soreness for 2-3 days, similar to a minor muscle bruise. Regular physical activities can be resumed after the biopsy. However, it is advised to avoid swimming.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participants' maximal oxygen uptake is determined through a test on a cycle ergometer before the start of the experiment. The test begins with a 20-minute warm-up at two different low workloads, after which the workload is gradually increased until the predetermined cadence can no longer be maintained, or the participant indicates exhaustion. During the test, the participant's exhaled air is collected. After completing the warm-up, it typically takes between 4 and 7 minutes to complete the test.
Study: NCT06775743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIENT-31 regimen
Description: Sintilimab plus bevacizumab plus platinum-doublet chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Based on the results of the response evaluation, personalized SBRT will be arranged after cycle 4:~A. Complete response, CR: continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression, intolerable toxic side effects, or up to two years.~B. Stable disease, SD/partial response, PR: if the residual lesions do not exceed three organs and five lesions, and if the investigator deems SBRT feasible, curative-dose stereotactic radiotherapy covering all residual lesions will be administered, with dosing based on the NRG-BR001 study.~C. If the residual lesions exceed three organs or five lesions, SBRT (24 Gy/3 Fx) targeting 1-3 selected tumor lesions will be performed, and then continue with maintenance therapy of PD-1 antibody + pemetrexed + VEGF antibody until disease progression.~D. Progressive disease, PD: subsequent treatment is conducted according to the standard guidelines.
Study: NCT06776302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Raise of blood flow through the brain
Description: At each patient two test are preformed. The first test is based on increasing blood flow through the brain through a controlled gradual infusion of norepinephrine (noradrenalin). The patient will receive such an infusion immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission. The second test is based on passive elevation of the lower extremities. The second test will also be performed on the patient immediately upon admission and stabilization in the Department of Intensive Internal Medicine and then in the period of 6, 12, 24, 48 and 72 hours after admission.
Study: NCT06775587

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Raman spectroscopy intelligent diagnostic system
Description: 1. Screening interested participants should sign the appropriate informed consent (ICF) prior to completion any study procedures.~2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.~3. The following is the general sequence of events during the 3 months evaluation period:~4. Completion of baseline procedures Participants were assessed for 3 months and completed all safety monitoring.
Study: NCT06781463

Intervention type: OTHER
Intervention: Registry (N/A)
Description: This study is a registry, thus no research intervention is being directly tested.
Study: NCT06780072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activation Massage therapy
Description: Massage Sessions~Activation (Sports) massage The activation (sports) type of massage will be used as one of the massage interventions. This technique will be performed on a full body with more attention given to specific leg muscle groups such as the feet, the gastrocnemius, the femoral biceps and quadriceps and in upper body muscle groups such as the triceps, the rhomboid, the deltoid, the trapezius and head areas. Briefly, this type of massage involves a wide range of techniques that include effleurage, palmar sliding, pounding and hacking. The total duration of the activation message will be 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Massage Therapy
Description: Relaxation massage The Relaxation type of massage will be used as the second type of intervention in this study. This technique is designed to promote deep relaxation, reduce stress and enhance overall well-being. It is characterized by the use of four primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage
Study: NCT06780215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate Tablets
Description: Subjects in treatment group take varenicline tartrate tablets according to the following regimen:~Days 1-3: 0.5 mg/dose, once daily. Days 4-42: 0.5 mg/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 0.5 mg/dose, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-3: 1 tablet/dose, once daily. Days 4-42: 1 tablet/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 1 tablet/dose, once daily.
Study: NCT06780605

Intervention type: GENETIC
Intervention: niPGT-A
Description: After being thawed following the standard lab practice, any donated blastocyst usable for the study will be washed individually to remove any trace of cumulus DNA and will be transferred to a new culture dish with a drop of 10-15µl. Day-5 blastocysts with proper re-expansion after thawing, will be cultured overnight (≈24 hours) before media collection and TE/ICM biopsies. Day-6 blastocysts will be cultured a total of 8 hours after thawing, before media collection and TE/ICM biopsies.~On day 6/7, the embryos' media will be collected with an automatic pipette for niPGT-A and additional genetic analysis. The same protocol will be used to analyze SBM and blastocyst biopsies.

Intervention type: GENETIC
Intervention: Multifocal TE biopsies and ICM biopsy
Description: For biopsy, blastocysts will be transferred to the biopsy dish and multi-focal TE biopsies will be performed in three locations related to the position of the ICM. ICM biopsies will be performed following a published protocol provided to the participant centers. ICM and TE sections will be aspirated with the use of micropipettes adapted to a micromanipulation and laser microscope system.~For the genetic study of the samples, the same protocol will be used to analyze embryo biopsies and SBM.
Study: NCT06781853

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The intervention consists of 12 weekly one-on-one online CBT sessions, each lasting 50 minutes, delivered via Microsoft Teams. The sessions will focus on addressing symptoms of muscle dysmorphia (MD), maladaptive thought patterns, and behaviors associated with steroid and performance-enhancing drug (PED) use. The therapy is based on structured CBT techniques and will include psychoeducation, cognitive restructuring, behavioral experiments, and relapse prevention strategies. The sessions will be conducted by trained clinical psychology master's students under the supervision of experienced clinical psychologists and a psychiatrist. The intervention is designed to reduce MD symptoms and improve psychological well-being.